论文部分内容阅读
目的:探讨超声造影(CEUS)定量分析在结直肠癌肝转移辅以贝伐单抗联合细胞毒性化疗及仅细胞毒性化疗早期疗效评价中的应用价值。方法:将28例结直肠癌肝转移患者分成贝伐单抗联合mFOLFOX6治疗组与mFOLFOX6治疗组,每组各14例。于第1~4次化疗前1d行常规超声及CEUS,采用动态造影定量分析软件,记录患者肝脏病灶的各项定量参数,根据实体瘤疗效评价标准(RECIST)最终结果,分别比较两治疗组中有效患者与无效患者第1次化疗前1d与第2次化疗前1d病灶定量参数变化百分数的差异。结果:贝伐单抗联合mFOLFOX6治疗组有效患者与无效患者病灶定量参数峰值强度(PI)变化百分数差异有统计学意义(P=0.03),余参数差异无统计学意义(均P>0.05);mFOLFOX6治疗组有效患者与无效患者病灶各参数变化百分数比较差异均无统计学意义(均P>0.05)。结论:CEUS定量参数P1对于结直肠癌肝转移贝伐单抗联合细胞毒性化疗早期疗效评价有一定应用价值。
Objective: To investigate the value of CEUS quantitative analysis in evaluating the early curative effect of liver metastasis of colorectal cancer with bevacizumab combined with cytotoxic chemotherapy and cytotoxic chemotherapy alone. Methods: 28 patients with liver metastasis of colorectal cancer were divided into bevacizumab combined mFOLFOX6 treatment group and mFOLFOX6 treatment group, 14 cases in each group. Conventional ultrasound and CEUS were performed 1 day before the first to the fourth chemotherapy. Quantitative dynamic analysis software was used to record the quantitative parameters of the liver lesions. According to the final results of the RECIST, the differences between the two treatment groups The differences of quantitative parameters between the first and the second pre-chemotherapy 1d before and after the first chemotherapy in the effective patients and the invalid patients were compared. Results: The difference of peak intensity (PI) percentage of quantitative parameters between effective and invalid patients in bevacizumab plus mFOLFOX6 group was statistically significant (P = 0.03). There was no significant difference in the remaining parameters (all P> 0.05). There was no significant difference in the percentage change of the parameters between the active and inactive patients in the mFOLFOX6 treatment group (all P> 0.05). Conclusion: CEUS quantitative parameter P1 has certain value in early curative evaluation of colorectal cancer combined with bevacizumab and cytotoxic chemotherapy.